Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C12H14N2O2 |
| Molecular Weight | 218.2518 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=O)CN1C[C@H](CC1=O)C2=CC=CC=C2
InChI
InChIKey=LYONXVJRBWWGQO-JTQLQIEISA-N
InChI=1S/C12H14N2O2/c13-11(15)8-14-7-10(6-12(14)16)9-4-2-1-3-5-9/h1-5,10H,6-8H2,(H2,13,15)/t10-/m0/s1
| Molecular Formula | C12H14N2O2 |
| Molecular Weight | 218.2518 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:12:39 UTC 2023
by
admin
on
Sat Dec 16 10:12:39 UTC 2023
|
| Record UNII |
X4X99EKB3S
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
949925-07-9
Created by
admin on Sat Dec 16 10:12:40 UTC 2023 , Edited by admin on Sat Dec 16 10:12:40 UTC 2023
|
PRIMARY | |||
|
100000164662
Created by
admin on Sat Dec 16 10:12:40 UTC 2023 , Edited by admin on Sat Dec 16 10:12:40 UTC 2023
|
PRIMARY | |||
|
781883
Created by
admin on Sat Dec 16 10:12:40 UTC 2023 , Edited by admin on Sat Dec 16 10:12:40 UTC 2023
|
PRIMARY | |||
|
X4X99EKB3S
Created by
admin on Sat Dec 16 10:12:40 UTC 2023 , Edited by admin on Sat Dec 16 10:12:40 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
RACEMATE -> ENANTIOMER |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: Merz Pharma; Mechanism of Action: Dopamine uptake inhibitor; Orphan Drug Status: No;
On Fast track: No; New Molecular Entity: Yes; Highest Development Phase: Phase I for Fatigue
Most Recent Event: 08 Jun 2014 Phase-I clinical trials in Fatigue (In volunteers) in Germany (unspecified route)
|
||
|
ACTIVE MOIETY |
At the doses 25-100 mg/kg i.p. the drug induced dose-dependent ipsilateral rotations in rats with unilateral 6-hydroxydopamine (6-OHDA)-induced nigrostriatal system lesions. However, MRZ-9547 enhanced contralateral rotation produced by L-DOPA given at an effective (25 mg/kg i.p.), but not at a sub-effective (6.25 mg/kg i.p.) dose. Microdialysis experiments revealed that MRZ-9547 penetrated well to the brain and did not show any pharmacokinetic interaction with L-DOPA. In unilaterally 6-OHDA-lesioned rats having developed abnormal involuntary movements (AIMs, a rodent correlate of LID) after chronic L-DOPA treatment, MRZ-9547 (50 mg/kg i.p.) did not significantly affect the AIMs expression. The results indicate that MRZ-9547 may by itself have antiparkinsonian activity at early stages of the disease, when some dopaminergic terminals are still intact. It may also enhance antiparkinsonian effect of L-DOPA. MRZ-9547 does not seem to influence the expression of LID in 6-OHDA-lesioned rats. The results support the use of MRZ-9547 in PD patients treated with L-DOPA.
|
||
|
ACTIVE MOIETY |
Results reveal that MRZ-9547 is a selective dopamine transporter (DAT) inhibitor that moderately stimulated striatal dopamine release. MRZ-9546 was a much less potent DAT inhibitor. Furthermore, MRZ-9547 dose dependently increased the tendency to work for food reinforcement both in the standard PR task and the PR/chow feeding choice task, MRZ-9546 was considerably less active. Relative to MRZ-9547, other DAT-interfering drugs had only moderate (methylphenidate) or marginal (modafinil, d-amphetamine) stimulant effects on PR responding in either task. Collectively, our data demonstrate that the DAT inhibitor MRZ-9547 can markedly stimulate PR responding and shift effort-related decision making in intact rats towards high-effort response options. An analysis of effort-related decision making in rodents could provide an animal model for motivational dysfunctions related to effort expenditure such as fatigue, e.g. in Parkinson's disease or major depression.
|
